Thin EBUS Pilot Study

Clinical Evaluation of the Thin TCP-EBUS Bronchoscopy System

NCT04745962•Medical University of South Carolina

Summary

This is a single-center pilot study at the Medical University of South Carolina (MUSC) to evaluate the safety and efficacy of the TCP-EBUS scope (Thin EBUS). This study will consist of a standard of care bronchoscopy and will be followed for approximately 3 months. While the device is not FDA approved, it is the same technology but a thinner version of the SCP-EBUS bronchoscope.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Willing and able to provide informed consent.
•2. \>21 years of age or older.
•3. Target lesion(s) within the middle third of the lung, which will be determined radiographically prior to scheduling the procedure by the bronchoscopist or radiologist, or by being located at least 2 airway generations from the main carina as seen radiographically.
•4. Target lesion(s) location documented on CT scan report.
•5. Indicated for bronchosocpy.
•6. Bronchoscopic procedure scheduled within 30 days of the CT scan report.

Exclusion Criteria

•1. Not suitable for flexible bronchoscopy as determined by the treating physician prior to the procedure.
•2. Currently on anticoagulation medications with INR \>1.5.
•3. Currently using DOAC and does not suspend use at least 7 days prior to the index procedure
•4. Currently using Plavix and does not suspend use for at least 7 days prior to the index procedure.

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Key Dates

Start Date

September 9, 2020

Primary Completion Date

September 28, 2024

Completion Date

September 28, 2024

Last Updated

February 2, 2026

Enrollment

ACTUAL participants

Conditions

Lung; Node

Interventions

Slimscope

DEVICE

Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules

NCT05306912

Lung CancerLung; Node

View study

NOT_YET_RECRUITING

From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.

NCT05801406

Lung CancerLung Non-Small Cell Carcinoma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 2, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Thin EBUS Pilot Study

Inclusion Criteria

Exclusion Criteria

Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules

From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.

Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions

The Early Diagnosis of Pulmonary Nodule Based on Multi-dimension Messages